The epidermal growth factor receptor as a target for cancer therapy

Endocrine-Related Cancer

Volumn 8, Issue 1, 2001, Pages 3-9

  Mendelsohn, J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CETUXIMAB; CHIMERIC PROTEIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225; PACLITAXEL; THYROTROPIN RECEPTOR; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOCRINE EFFECT; BINDING SITE; CANCER THERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CHIMERA; CONFERENCE PAPER; HUMAN; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0034988184     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080003     Document Type: Conference Paper

References (66)

1. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
2. Serum-free cell culture: A unifying approach
3. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
4. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts
5. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
6. Combined response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies
7. PD 153035, a tyrosine kinase inhibitor, prevents receptor activation and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor in a dose and receptor number dependent manner
8. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms
9. 1 arrest and enhancing the antitumor effect of interferon
10. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
11. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein
12. 1 arrest induced by deprivation of epidermal growth factor
13. Antitumor activity of sequential treatment with Topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
14. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
15. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal
16. Epidermal growth factor receptor-kinase interactions: Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity
17. Similarities and differences between the effect of epidermal growth factor and Rous sarcoma virus
18. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
19. Evidence that viral transforming gene products and epidermal growth factor stimulate phosphorylation of the same cellular protein with similar specificity
20. Induction of apoptosis in fibroblasts by c-myc protein
21. Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
22. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
23. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
24. Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors
25. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
26. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α
27. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
28. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
29. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
30. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
31. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
32. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
33. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
34. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma in A431 cells
35. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors
36. Inhibitors of tyrosine kinase
37. Tyrosine kinase inhibition: An approach to drug development
38. Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells
39. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity
40. Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells
41. Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor receptor in normal and adenomatous human colon epithelium
42. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
43. Apoptosis and the cell cycle
44. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
45. Blockade of receptors for growth factors: An anti-cancer therapy
46. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
47. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
48. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
49. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
50. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
51. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas
52. 1 arrest in prostatic cancer cell line DU145
53. Tumor epidermal growth factor receptor studies in patients with non-small cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
54. Tumor studies in patients with head and neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin
55. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
56. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
57. Epidermal growth factor-related peptides and their receptors in human malignancies
58. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
59. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
60. Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
61. Autocrine secretion and malignant transformation of cells
62. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth
63. Human epidermal growth factor receptor cRNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
64. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
65. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
66. Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells